The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
The LAM Foundation
4015 Executive Park Drive, Suite 320
Cincinnati, OH 45241
The LAM Foundation is an international, non-profit organization dedicated to finding a cure for lymphangioleiomyomatosis (LAM). The LAM Foundation is a rare progressive lung disease that affects females, usually of childbearing age. The disease is characterized by the abnormal growth of smooth muscle, leading to airway obstruction and cystic lesions (blebs) in the lungs. The symptoms of lymphangioleiomyomatosis may include shortness of breath, coughing, and/or difficulty breathing (dyspnea), especially following periods of exercise or exertion. Affected individuals may experience repeated episodes of chest pain due to fluid accumulations around the lungs (pleural effusions), potentially resulting in collapse of a lung (pneumothorax). The exact cause of lymphangioleiomyomatosis is not known. Founded in 1995, the organization believes that the cause of the disease will be uncovered by scientific research. The LAM Foundation's main objectives are to support efforts by the scientific community to develop better methods of prevention, diagnosis, and treatment; to undertake activities that will increase the amount of funding nationwide to support research on LAM; and to serve as an information resource to women affected by LAM and their families.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and that credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions are strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.